Bristol-Myers Squibb Co (BMY) Shares Bought by Benedict Financial Advisors Inc.

Benedict Financial Advisors Inc. boosted its holdings in Bristol-Myers Squibb Co (NYSE:BMY) by 4.0% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 25,248 shares of the biopharmaceutical company’s stock after buying an additional 974 shares during the period. Benedict Financial Advisors Inc.’s holdings in Bristol-Myers Squibb were worth $1,567,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of the business. Principal Financial Group Inc. lifted its stake in shares of Bristol-Myers Squibb by 7.9% in the 1st quarter. Principal Financial Group Inc. now owns 3,094,134 shares of the biopharmaceutical company’s stock valued at $195,704,000 after purchasing an additional 225,999 shares in the last quarter. Fisher Asset Management LLC raised its holdings in shares of Bristol-Myers Squibb by 0.7% during the 2nd quarter. Fisher Asset Management LLC now owns 581,310 shares of the biopharmaceutical company’s stock valued at $32,170,000 after buying an additional 4,229 shares during the period. Trust Co. of Vermont raised its holdings in shares of Bristol-Myers Squibb by 1.9% during the 2nd quarter. Trust Co. of Vermont now owns 67,276 shares of the biopharmaceutical company’s stock valued at $3,723,000 after buying an additional 1,256 shares during the period. Xact Kapitalforvaltning AB raised its holdings in shares of Bristol-Myers Squibb by 3.6% during the 2nd quarter. Xact Kapitalforvaltning AB now owns 331,210 shares of the biopharmaceutical company’s stock valued at $18,329,000 after buying an additional 11,384 shares during the period. Finally, First Citizens Bank & Trust Co. raised its holdings in shares of Bristol-Myers Squibb by 26.4% during the 2nd quarter. First Citizens Bank & Trust Co. now owns 10,851 shares of the biopharmaceutical company’s stock valued at $601,000 after buying an additional 2,268 shares during the period. 72.54% of the stock is currently owned by hedge funds and other institutional investors.

BMY stock opened at $52.81 on Friday. The company has a current ratio of 1.53, a quick ratio of 1.40 and a debt-to-equity ratio of 0.41. Bristol-Myers Squibb Co has a 52-week low of $46.94 and a 52-week high of $70.05. The company has a market cap of $83.81 billion, a price-to-earnings ratio of 17.54, a price-to-earnings-growth ratio of 1.43 and a beta of 1.08.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, October 25th. The biopharmaceutical company reported $1.09 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.91 by $0.18. Bristol-Myers Squibb had a return on equity of 47.89% and a net margin of 6.50%. The company had revenue of $5.69 billion for the quarter, compared to the consensus estimate of $5.72 billion. On average, equities analysts forecast that Bristol-Myers Squibb Co will post 3.88 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, November 1st. Shareholders of record on Friday, October 5th were issued a dividend of $0.40 per share. The ex-dividend date was Thursday, October 4th. This represents a $1.60 annualized dividend and a yield of 3.03%. Bristol-Myers Squibb’s dividend payout ratio is presently 53.16%.

Several brokerages recently commented on BMY. SunTrust Banks reiterated a “buy” rating and set a $67.00 target price on shares of Bristol-Myers Squibb in a report on Tuesday, July 31st. JPMorgan Chase & Co. raised their target price on Bristol-Myers Squibb from $70.00 to $74.00 and gave the company an “overweight” rating in a report on Monday, October 8th. ValuEngine upgraded Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a report on Saturday, July 14th. BMO Capital Markets raised their target price on Bristol-Myers Squibb from $47.00 to $51.00 and gave the company a “market perform” rating in a report on Monday, July 23rd. Finally, William Blair reiterated an “outperform” rating on shares of Bristol-Myers Squibb in a report on Monday, October 22nd. Two research analysts have rated the stock with a sell rating, twelve have given a hold rating and seven have issued a buy rating to the company’s stock. Bristol-Myers Squibb currently has a consensus rating of “Hold” and a consensus target price of $62.48.

COPYRIGHT VIOLATION WARNING: This article was reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this article on another domain, it was copied illegally and reposted in violation of international copyright and trademark law. The correct version of this article can be accessed at https://sportsperspectives.com/2018/11/09/bristol-myers-squibb-co-bmy-shares-bought-by-benedict-financial-advisors-inc.html.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection.

Read More: Capital Gains

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply